Case number 1:15-cv-00202
AstraZeneca LP et al v. Mylan Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 4, 2015 | 1 | Main Document (14) |
| Nov 4, 2015 | 1 | Exhibit A - US Patent Information (52) |
| Nov 4, 2015 | 2 | Exhibit B - US Patent Information (15) |
| Nov 4, 2015 | 3 | Exhibit C - US Patent Information (17) |
| Nov 4, 2015 | 3 | Other Document (2) |
| Nov 4, 2015 | 4 | Exhibit D - US Patent Information (17) |
| Nov 4, 2015 | 5 | Exhibit E - US Patent Information (8) |
| Nov 4, 2015 | 6 | Civil Cover Sheet (2) |
| Nov 4, 2015 | 1 | Main Document (14) |
| Nov 4, 2015 | 1 | Exhibit A - US Patent Information (52) |
| Nov 4, 2015 | 5 | Corporate Disclosure Statement (2) |
| Nov 4, 2015 | 2 | Exhibit B - US Patent Information (15) |
| Nov 4, 2015 | 3 | Other Document (2) |
| Nov 4, 2015 | 3 | Exhibit C - US Patent Information (17) |
| Nov 4, 2015 | 4 | Exhibit D - US Patent Information (17) |
| Nov 4, 2015 | 5 | Exhibit E - US Patent Information (8) |
| Nov 4, 2015 | 1 | Main Document (14) |
| Nov 4, 2015 | 6 | Civil Cover Sheet (2) |
| Nov 4, 2015 | 1 | Exhibit A - US Patent Information (52) |
| Nov 4, 2015 | 4 | Corporate Disclosure Statement (2) |
| Nov 4, 2015 | 2 | Exhibit B - US Patent Information (15) |
| Nov 4, 2015 | 3 | Exhibit C - US Patent Information (17) |
| Nov 4, 2015 | 4 | Exhibit D - US Patent Information (17) |
| Nov 4, 2015 | 1 | Main Document (14) |
| Nov 4, 2015 | 5 | Exhibit E - US Patent Information (8) |
| Nov 4, 2015 | 1 | Exhibit A - US Patent Information (52) |
| Nov 4, 2015 | 3 | Other Document (2) |
| Nov 4, 2015 | 6 | Civil Cover Sheet (2) |
| Nov 4, 2015 | 2 | Exhibit B - US Patent Information (15) |
| Nov 4, 2015 | 3 | Exhibit C - US Patent Information (17) |
| Nov 4, 2015 | 4 | Exhibit D - US Patent Information (17) |
| Nov 4, 2015 | 5 | Exhibit E - US Patent Information (8) |
| Nov 4, 2015 | 3 | Other Document (2) |
| Nov 4, 2015 | 6 | Civil Cover Sheet (2) |
| Nov 4, 2015 | 6 | Corporate Disclosure Statement (2) |
| Nov 4, 2015 | 7 | Corporate Disclosure Statement (2) |
